BR112020019979A2 - Composições e métodos para tratamento de doenças inflamatórias intestinais - Google Patents

Composições e métodos para tratamento de doenças inflamatórias intestinais Download PDF

Info

Publication number
BR112020019979A2
BR112020019979A2 BR112020019979-6A BR112020019979A BR112020019979A2 BR 112020019979 A2 BR112020019979 A2 BR 112020019979A2 BR 112020019979 A BR112020019979 A BR 112020019979A BR 112020019979 A2 BR112020019979 A2 BR 112020019979A2
Authority
BR
Brazil
Prior art keywords
acid
fact
subject
secondary bile
oxo
Prior art date
Application number
BR112020019979-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Madhumitha NANDAKUMAR
Edward J. O'Brien
Sumon Datta
Original Assignee
Seres Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seres Therapeutics, Inc. filed Critical Seres Therapeutics, Inc.
Publication of BR112020019979A2 publication Critical patent/BR112020019979A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112020019979-6A 2018-03-29 2019-03-29 Composições e métodos para tratamento de doenças inflamatórias intestinais BR112020019979A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650002P 2018-03-29 2018-03-29
US62/650,002 2018-03-29
PCT/US2019/025010 WO2019191694A1 (en) 2018-03-29 2019-03-29 Compositions and methods for treating inflammatory bowel diseases

Publications (1)

Publication Number Publication Date
BR112020019979A2 true BR112020019979A2 (pt) 2021-03-09

Family

ID=66429534

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020019979-6A BR112020019979A2 (pt) 2018-03-29 2019-03-29 Composições e métodos para tratamento de doenças inflamatórias intestinais

Country Status (10)

Country Link
US (1) US20210121505A1 (https=)
EP (1) EP3773643A1 (https=)
JP (1) JP2021519763A (https=)
KR (1) KR20200138333A (https=)
CN (1) CN112118852A (https=)
AU (1) AU2019245430A1 (https=)
BR (1) BR112020019979A2 (https=)
CA (1) CA3095402A1 (https=)
MX (1) MX2020010177A (https=)
WO (1) WO2019191694A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
TW202126317A (zh) 2019-09-24 2021-07-16 美商普拉塔生技公司 用於治療發炎和免疫疾病之組成物和方法
KR102341323B1 (ko) * 2020-07-07 2021-12-21 한국원자력의학원 미세플라스틱 노출에 의해 유도되는 뇌질환 예후 예측용 바이오마커 조성물 및 이를 이용한 예후 예측방법
CA3188645A1 (en) 2020-08-14 2022-02-17 Prolacta Bioscience, Inc. Human milk oligosaccharide compositions for use with bacteriotherapies
KR102337993B1 (ko) * 2021-10-27 2021-12-14 주식회사 바이오뱅크힐링 클로스트리디움 렙텀 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN115478031B (zh) * 2022-09-28 2025-04-18 中国科学院深圳先进技术研究院 防治炎症性肠病的胆汁酸代谢菌及其应用
WO2025244478A1 (ko) * 2024-05-24 2025-11-27 서울대학교병원 클로스트리디움 렙텀 균주의 염증성장질환 예방, 치료 및 진단 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013035804A1 (ja) * 2011-09-08 2013-03-14 カルピス株式会社 芽胞形成菌の発芽誘起方法
JP5921894B2 (ja) * 2012-01-20 2016-05-24 アサヒカルピスウェルネス株式会社 腸内酪酸産生菌増加剤
CA2899925A1 (en) * 2013-02-04 2014-08-07 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US20190247447A1 (en) * 2015-11-24 2019-08-15 Seres Therapeutics, Inc. Designed bacterial compositions
JP6624903B2 (ja) * 2015-11-25 2019-12-25 学校法人東京理科大学 消毒剤及び消毒方法
WO2017160711A1 (en) * 2016-03-14 2017-09-21 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
CN110545828A (zh) * 2016-04-19 2019-12-06 基因组研究有限公司 细菌疗法
JP7168558B2 (ja) * 2016-06-14 2022-11-09 ヴェダンタ バイオサイエンシーズ インコーポレーテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置
EP3668527A1 (en) * 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
JP2021501185A (ja) * 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法

Also Published As

Publication number Publication date
US20210121505A1 (en) 2021-04-29
JP2021519763A (ja) 2021-08-12
CA3095402A1 (en) 2019-10-03
RU2020135433A (ru) 2022-04-29
KR20200138333A (ko) 2020-12-09
WO2019191694A1 (en) 2019-10-03
CN112118852A (zh) 2020-12-22
AU2019245430A1 (en) 2020-10-22
EP3773643A1 (en) 2021-02-17
MX2020010177A (es) 2021-01-15

Similar Documents

Publication Publication Date Title
US12318412B2 (en) Faecalibacterium prausnitzii and Desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases
BR112020019979A2 (pt) Composições e métodos para tratamento de doenças inflamatórias intestinais
BR112020023933A2 (pt) composições bacterianas projetadas e usos destas
Bringiotti et al. Intestinal microbiota: the explosive mixture at the origin of inflammatory bowel disease?
JP2023010890A (ja) 潰瘍性大腸炎を治療するための方法
CN114650833A (zh) 用于治疗孤独症谱群障碍的组合物和方法
CN102333534B (zh) 用于治疗胃溃疡和十二指肠溃疡的包括质子泵抑制剂及益生元的药物组合物
AU2008310961B2 (en) Probiotics for use in relieving symptoms associated with gastrointestinal disorders
CN113474447A (zh) 菌株、组合物和使用方法
US20210275603A1 (en) Compositions and Methods for Treating Irritable Bowel Syndrome and Related Disorders
JP2020533008A (ja) Ｍｅｇａｍｏｎａｓ ｆｕｎｉｆｏｒｍｉｓ及びその適用
KR20180122380A (ko) 피칼리박테리움속 세균증식제
US20180099011A1 (en) Compositions and Methods for Treating Irritable Bowel Syndrome and Related Disorders
CN119799585A (zh) 一种润肠通便、提高肠道免疫的复合益生菌及其应用
RU2799556C2 (ru) Композиции и способы лечения воспалительных заболеваний кишечника
US20190091270A1 (en) Probiotics for use in relieving symptoms associated with gastrointestinal disorders
RU2797466C2 (ru) Faecalibacterium prausnitzii и desulfovibrio piger для применения при лечении или предупреждении диабета и заболеваний кишечника
CN106974940A (zh) 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
HK40079150A (en) Compositions and methods for treating autism spectrum disorder
HK1146914B (en) Pharmaceutical compositions comprising l. acidophilus and bifidobacterium lactis for use in the treatment of functional bowel disorder

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.